Literature DB >> 9048488

A PCR-RFLP method for the detection of activated H-ras oncogene with a point mutation at codon 12 and 61.

S J Hong1, T Lee, Y S Park, K O Lee, B H Chung, S H Lee.   

Abstract

To investigate the incidence of the H-ras gene activation in bladder tumor and the feasibility of using urinary washout samples for screening, a series of 33 human bladder tumors and their preoperatively collected urinary washout samples were screened using a mutant specific PCR-RFLP (polymerase chain-restriction fragment length polymorphism) to detect a point mutation of the H-ras gene. Five tumors were found to harbor H-ras mutations where two tumors had a glycine to valine (G-->T) change in codon 12 and three tumors had a glutamine to lysine (C-->A) change in codon 61, respectively. Moreover, we could also detect the same point mutations of the H-ras gene in corresponding urine washout samples. The incidence of H-ras mutation in Korean bladder cancer was estimated at approximately 15.2%. In conclusion, a mutant specific PCR-RFLP method for the detection of H-ras gene mutation is useful for screening or postoperative follow-up of bladder tumor due to its simplicity and high specificity even in urinary samples.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9048488     DOI: 10.3349/ymj.1996.37.6.371

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  3 in total

1.  Inhibitory effect of flavonoids on mutant H-Rasp protein.

Authors:  Tariq A Masoodi; Adel H Alhamdanz
Journal:  Bioinformation       Date:  2010-06-15

2.  H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells.

Authors:  C Li; R-H Teng; Y-C Tsai; H-S Ke; J-Y Huang; C-C Chen; Y-L Kao; C-C Kuo; W R Bell; B Shieh
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

3.  Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.

Authors:  R Abdel-Fattah; C Challen; T R Griffiths; M C Robinson; D E Neal; J Lunec
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.